# Revolution Medicines, Inc.

Summary updated: 2026-10-02T11:10:52.943679Z
Canonical: https://finbar.com/research/companies/revolution-medicines-inc

## Overview

Revolution Medicines, Inc. is a U.S. oncology biopharmaceutical company developing targeted medicines for cancers driven by RAS mutations. Its approach focuses on inhibiting active, GTP-bound RAS proteins. The company’s first commercial product, RASONQUE (daraxonrasib), was approved for certain adults with metastatic pancreatic adenocarcinoma in August 2026; its pipeline also includes candidates targeting RAS G12C, G12D, and G12V. [1](https://app.finbar.com/go?id=P147111305)[2](https://app.finbar.com/go?id=P78242533)[3](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)

The company states its mission is to revolutionize treatment for people with RAS-addicted cancers by discovering, developing, and delivering targeted medicines. It is headquartered in Redwood City, California, and has pursued international reach through partnerships, including a 2026 agreement covering development and commercialization rights in select Asian markets. [4](https://www.revmed.com/revolution-ras/)[5](https://app.finbar.com/go?id=P90805969)[6](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical)

Revolution Medicines reported no revenue for 2025, before its first product approval, and reported $3.9 billion in cash, cash equivalents, and marketable securities as of June 30, 2026. [7](https://app.finbar.com/go?id=T10277296)[8](https://app.finbar.com/go?id=P147111296)
[1](https://app.finbar.com/go?id=P147111305)[2](https://app.finbar.com/go?id=P78242533)[3](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)[4](https://www.revmed.com/revolution-ras/)[5](https://app.finbar.com/go?id=P90805969)[6](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical)[7](https://app.finbar.com/go?id=T10277296)[8](https://app.finbar.com/go?id=P147111296)[3](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)[4](https://www.revmed.com/revolution-ras/)[6](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical)

## Products & services

Revolution Medicines’ first marketed product is RASONQUE™ (daraxonrasib; RMC-6236), an oral RAS(ON) multi-selective tri-complex inhibitor. FDA-approved in August 2026 for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy, it is designed to inhibit cancer-driver RAS mutations at G12, G13 and Q61 across the three major RAS isoforms. The company is also developing daraxonrasib in other pancreatic-cancer settings. [9](https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib) [10](https://app.finbar.com/go?id=P147112684) [11](https://app.finbar.com/go?id=P147112705)

The clinical-stage pipeline includes zoldonrasib (RMC-9805), an oral, covalent RAS(ON) G12D-selective tri-complex inhibitor; elironrasib (RMC-6291), an oral RAS(ON) G12C-selective tri-complex inhibitor intended to target active RAS; and RMC-5127, an oral, non-covalent RAS(ON) G12V-selective tri-complex inhibitor. [12](https://app.finbar.com/go?id=P147112686) [13](https://app.finbar.com/go?id=P147112717) [14](https://app.finbar.com/go?id=P147112688) [15](https://app.finbar.com/go?id=P147112690) Earlier-stage programs include oral RMC-0708, a RAS(ON) Q61H-selective inhibitor; oral RMC-8839, a covalent RAS(ON) G13C-selective inhibitor; and RM-055, a preclinical mutant-targeted catalytic RAS(ON) inhibitor. [16](https://app.finbar.com/go?id=P147112682) [17](https://app.finbar.com/go?id=P147112697) [18](https://app.finbar.com/go?id=P147112699) [19](https://app.finbar.com/go?id=P147112694)

The company’s identified offerings are drug products and development programs; the reviewed materials do not identify separate commercial services. The latest quarterly filing reviewed covers the period ended June 30, 2026, before RASONQUE’s approval, and does not report product sales; no product-revenue percentage or post-approval sales performance is established by that filing. [20](https://app.finbar.com/go?id=T16831819) [21](https://app.finbar.com/go?id=D354376) [22](https://app.finbar.com/go?id=D280741)
[10](https://app.finbar.com/go?id=P147112684)[11](https://app.finbar.com/go?id=P147112705)[12](https://app.finbar.com/go?id=P147112686)[13](https://app.finbar.com/go?id=P147112717)[14](https://app.finbar.com/go?id=P147112688)[15](https://app.finbar.com/go?id=P147112690)[16](https://app.finbar.com/go?id=P147112682)[17](https://app.finbar.com/go?id=P147112697)[18](https://app.finbar.com/go?id=P147112699)[19](https://app.finbar.com/go?id=P147112694)[20](https://app.finbar.com/go?id=T16831819)[21](https://app.finbar.com/go?id=D354376)[22](https://app.finbar.com/go?id=D280741)[9](https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib)[9](https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib)

## Geographic presence

Revolution Medicines is headquartered at 700 Saginaw Drive in Redwood City, California. Its 2025 annual report describes office, laboratory and research-and-development space at several Saginaw Drive addresses in Redwood City; the company’s Q2 2026 filing says its operating leases primarily cover office, laboratory and R&D space there. [23](https://app.finbar.com/go?id=P147112394)[5](https://app.finbar.com/go?id=P90805969)[24](https://app.finbar.com/go?id=P25011082)[25](https://app.finbar.com/go?id=P147112569) The company’s official contact page also lists its Redwood City headquarters. [26](https://www.revmed.com/contact-us/)

The latest available filing in the reviewed materials is the Q2 2026 Form 10-Q; the latest annual report is for 2025. Those filings do not provide a geographic breakdown of revenue or employees. The Q2 2026 filing says the company relies substantially on third parties for preclinical studies, clinical trials and manufacturing, but does not specify where those activities take place. [27](https://app.finbar.com/go?id=P147112752)
[23](https://app.finbar.com/go?id=P147112394)[5](https://app.finbar.com/go?id=P90805969)[24](https://app.finbar.com/go?id=P25011082)[25](https://app.finbar.com/go?id=P147112569)[26](https://www.revmed.com/contact-us/)[27](https://app.finbar.com/go?id=P147112752)[26](https://www.revmed.com/contact-us/)

## Business segments

Revolution Medicines reports one operating and reportable segment, managed on a consolidated basis. The company does not identify separate reportable segments by drug, cancer type, or development program; accordingly, it provides no segment-by-segment contribution percentages. [28](https://app.finbar.com/go?id=P147112509)

The segment’s business focus is developing targeted therapies for RAS-addicted cancers. Its RAS(ON) inhibitor programs include daraxonrasib (multi-selective), zoldonrasib (G12D-selective), elironrasib (G12C-selective), and RMC-5127 (G12V-selective), among other programs. These are pipeline areas, not separately reported segments. [29](https://app.finbar.com/go?id=P147112680)[16](https://app.finbar.com/go?id=P147112682)

The latest available filing cited here is the 2026 second-quarter Form 10-Q. It assesses segment performance using consolidated net loss; no percentage contribution by individual business segment is disclosed. [28](https://app.finbar.com/go?id=P147112509)[30](https://www.sec.gov/Archives/edgar/data/1628171/000119312526335104/rvmd-20260630.htm)
[28](https://app.finbar.com/go?id=P147112509)[29](https://app.finbar.com/go?id=P147112680)[16](https://app.finbar.com/go?id=P147112682)[30](https://www.sec.gov/Archives/edgar/data/1628171/000119312526335104/rvmd-20260630.htm)

## Company history

Revolution Medicines was incorporated on October 7, 2014, and publicly launched in February 2015 with a $45 million Series A financing led by Third Rock Ventures. Mark A. Goldsmith became president and CEO in 2014; Martin D. Burke was identified as a company founder. [31](https://www.sec.gov/Archives/edgar/data/1628171/000119312520040328/d848154dex31.htm) [32](https://ir.revmed.com/news-releases/news-release-details/third-rock-ventures-launches-revolution-medicines-45-million/) [33](https://app.finbar.com/go?id=P178226697) In 2017, the company appointed Stephen Kelsey president of research and development. [34](https://revmed.gcs-web.com/news-releases/news-release-details/revolution-medicines-appoints-cancer-leader-dr-stephen-kelsey)

In 2018, Revolution Medicines and Sanofi announced a global collaboration to develop SHP2-targeted cancer therapies, including RMC-4630. The company went public in February 2020, closing its initial public offering that month. [35](https://ir.revmed.com/news-releases/news-release-details/sanofi-and-revolution-medicines-launch-global-partnership) [36](https://app.finbar.com/go?id=P176356752) [37](https://app.finbar.com/go?id=P128675118) In November 2023, it completed its acquisition of EQRx, which became a wholly owned subsidiary. [38](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-completes-acquisition-eqrx/) [39](https://www.sec.gov/Archives/edgar/data/1628171/000119312524058009/d753996dex993.htm)

In 2026, the company reported positive Phase 3 results for daraxonrasib in second-line metastatic pancreatic cancer, and the FDA approved the drug, marketed as RASONQUE, for specified adults with metastatic pancreatic adenocarcinoma. [40](https://app.finbar.com/go?id=P84607371) [3](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)
[31](https://www.sec.gov/Archives/edgar/data/1628171/000119312520040328/d848154dex31.htm)[32](https://ir.revmed.com/news-releases/news-release-details/third-rock-ventures-launches-revolution-medicines-45-million/)[33](https://app.finbar.com/go?id=P178226697)[34](https://revmed.gcs-web.com/news-releases/news-release-details/revolution-medicines-appoints-cancer-leader-dr-stephen-kelsey)[35](https://ir.revmed.com/news-releases/news-release-details/sanofi-and-revolution-medicines-launch-global-partnership)[36](https://app.finbar.com/go?id=P176356752)[37](https://app.finbar.com/go?id=P128675118)[38](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-completes-acquisition-eqrx/)[39](https://www.sec.gov/Archives/edgar/data/1628171/000119312524058009/d753996dex993.htm)[40](https://app.finbar.com/go?id=P84607371)[3](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)[31](https://www.sec.gov/Archives/edgar/data/1628171/000119312520040328/d848154dex31.htm)[32](https://ir.revmed.com/news-releases/news-release-details/third-rock-ventures-launches-revolution-medicines-45-million/)[34](https://revmed.gcs-web.com/news-releases/news-release-details/revolution-medicines-appoints-cancer-leader-dr-stephen-kelsey)[35](https://ir.revmed.com/news-releases/news-release-details/sanofi-and-revolution-medicines-launch-global-partnership)[38](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-completes-acquisition-eqrx/)[39](https://www.sec.gov/Archives/edgar/data/1628171/000119312524058009/d753996dex993.htm)[3](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)

## Sources

1. [Revolution Medicines, Inc. — Press release (2026 Q 2)](https://app.finbar.com/go?id=P147111305)
2. [Revolution Medicines, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P78242533)
3. [www.fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)
4. [www.revmed.com](https://www.revmed.com/revolution-ras/)
5. [Revolution Medicines, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P90805969)
6. [ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical)
7. [Revolution Medicines, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T10277296)
8. [Revolution Medicines, Inc. — Press release (2026 Q 2)](https://app.finbar.com/go?id=P147111296)
9. [ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib)
10. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112684)
11. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112705)
12. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112686)
13. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112717)
14. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112688)
15. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112690)
16. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112682)
17. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112697)
18. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112699)
19. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112694)
20. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16831819)
21. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=D354376)
22. [Revolution Medicines, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=D280741)
23. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112394)
24. [Revolution Medicines, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P25011082)
25. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112569)
26. [www.revmed.com](https://www.revmed.com/contact-us/)
27. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112752)
28. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112509)
29. [Revolution Medicines, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147112680)
30. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1628171/000119312526335104/rvmd-20260630.htm)
31. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1628171/000119312520040328/d848154dex31.htm)
32. [ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/third-rock-ventures-launches-revolution-medicines-45-million/)
33. [Revolution Medicines, Inc. — Full financial report (2019 Y)](https://app.finbar.com/go?id=P178226697)
34. [revmed.gcs-web.com](https://revmed.gcs-web.com/news-releases/news-release-details/revolution-medicines-appoints-cancer-leader-dr-stephen-kelsey)
35. [ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/sanofi-and-revolution-medicines-launch-global-partnership)
36. [Revolution Medicines, Inc. — Full financial report (2020 Q 1)](https://app.finbar.com/go?id=P176356752)
37. [Revolution Medicines, Inc. — Press release (2020 Q 1)](https://app.finbar.com/go?id=P128675118)
38. [ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-completes-acquisition-eqrx/)
39. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1628171/000119312524058009/d753996dex993.htm)
40. [Revolution Medicines, Inc. — Press release (2026 Q 1)](https://app.finbar.com/go?id=P84607371)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.